From its current portfolio, ImmBio will license the following:
ImmBio is particularly interested in establishing partners in the following areas:
However, with a platform technology of broad utility, ImmBio would consider entering into discussions on the potential fit across the anti-infective landscape, where there is a strong rationale on the utility of the technology platform. |